The Oral GLP-1: Clinical Essentials
.png)
Oral semaglutide is the first GLP-1 receptor agonist licensed as a tablet for weight management in the UK, and demand in private practice is already building. This concise CPD module gives GPs, pharmacists and nurses the essentials to prescribe or advise with confidence. In one short lesson you will cover the licensed indication, how the tablet differs from Rybelsus, the safeguards expected of safe private prescribing, correct dosing and administration, how to switch a person from an injectable including Mounjaro, and the safety and counselling points that matter most.
This module is designed for registered UK healthcare professionals, including GPs, pharmacists, pharmacy technicians and nurses, who prescribe or advise on weight management medicines in private practice. It suits both those new to weight management prescribing and experienced prescribers who want a rapid, reliable update on the newest oral option.
This module is designed for continuing professional development and supports reflective practice. On completion you will be able to record your learning and a practice change for your CPD portfolio
The licensing of an oral weight-loss tablet changes the conversation in private practice, and it arrives at a time of close regulatory scrutiny. Prescribers are expected to verify eligibility properly, prescribe within the licence, and counsel clearly on safe use. Confusing the weight-management tablet with Rybelsus, or switching a person without managing expectations, are avoidable errors. This module is built to help you avoid them and to prescribe with confidence.
